The impact of biology on the treatment of secondary AML

MeSH terms

• Acute Disease
• Angiogenesis Inhibitors / therapeutic use
• Animals
• Antineoplastic Agents / therapeutic use*
• Antineoplastic Agents, Alkylating / adverse effects
• Antineoplastic Agents, Alkylating / therapeutic use
• Chromosome Deletion
• Chromosomes, Human, Pair 11 / genetics
• Chromosomes, Human, Pair 11 / ultrastructure
• Chromosomes, Human, Pair 7 / genetics
• Chromosomes, Human, Pair 7 / ultrastructure
• DNA Methylation
• DNA-Binding Proteins / genetics
• Enzyme Inhibitors / adverse effects
• Enzyme Inhibitors / therapeutic use
• Forecasting
• Genes, Tumor Suppressor
• Hematopoietic Stem Cells / drug effects
• Histone Deacetylase Inhibitors
• Histone-Lysine N-Methyltransferase
• Humans
• Leukemia, Experimental / etiology
• Leukemia, Experimental / pathology
• Leukemia, Myeloid / chemically induced
• Leukemia, Myeloid / drug therapy*
• Leukemia, Myeloid / genetics
• Leukemia, Radiation-Induced / pathology
• Mice
• Mice, Inbred NOD
• Mice, SCID
• Myeloid-Lymphoid Leukemia Protein
• Neoplasm Proteins / antagonists & inhibitors
• Neoplasms / drug therapy
• Neoplasms / radiotherapy
• Neoplasms, Second Primary / chemically induced
• Neoplasms, Second Primary / drug therapy*
• Neoplasms, Second Primary / genetics
• Neoplastic Stem Cells / drug effects
• Neovascularization, Pathologic / drug therapy
• Neovascularization, Pathologic / pathology
• Oncogene Proteins, Fusion / genetics
• Proto-Oncogenes*
• Stromal Cells / pathology
• Topoisomerase II Inhibitors
• Transcription Factors*
• Translocation, Genetic
• Xenograft Model Antitumor Assays